Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;39(7):e14827.
doi: 10.1111/dme.14827. Epub 2022 Mar 29.

Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service

Robert E J Ryder  1 , Mahi Yadagiri  1 , Wyn Burbridge  1 , Susan P Irwin  1 , Hardeep Gandhi  1 , Tahira Bashir  1 , Rachael A Allden  1 , Melanie Wyres  1 , Melissa Cull  1 , John P Bleasdale  1 , Edward N Fogden  1 , Mark R Anderson  1 , Piya Sen Gupta  1   2
Affiliations

Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the First National Health Service (NHS) EndoBarrier Service

Robert E J Ryder et al. Diabet Med. 2022 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None.

Figures

FIGURE 1
FIGURE 1
Weight and HbA1c at baseline, at removal and two‐years after removal in the 33/45(73%) who maintained most of the improvement (a) and 12/45(27%) who deteriorated to baseline (b). (a) Weight (mean ± SE): at baseline 123.9 ± 5.5 kg, at removal 105.3 ± 5.7 kg and 2‐years after removal 109.2 ± 5.4 kg. HbA1c (mean ± SE): at baseline 75.9 ± 3.4 mmol/mol (9.1 ± 0.3%), at removal 56.0 ± 1.9 mmol/mol (7.3 ± 0.2%) and 2‐years after removal 59.1 ± 2.7 mmol/mol (7.6 ± 0.2%). (b) Weight (mean ± SE): at baseline 118.7 ± 6.9 kg, at removal 105.1 ± 7.1 kg and 2‐years after removal 117.0 ± 7.1 kg. HbA1c (mean ± SE): at baseline 80.4 ± 5.4 mmol/mol (9.9 ± 0.6%), at removal 56.2 ± 3.6 mmol/mol (7.6 ± 0.5%) and two‐years after removal 90.2 ± 7.0 mmol/mol (10.6 ± 0.7%)
See this image and copyright information in PMC

References

    1. International Diabetes Federation . IDF diabetes atlas, 10th ed. 2021. (accessed 28 December 2021). https://www.diabetesatlas.org/
    1. Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal‐jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta‐analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care. 2018;41(5):1106‐1115. 10.2337/dc17-1985 - DOI - PubMed
    1. Laubner K, Riedel N, Fink K, et al. Comparative efficacy and safety of the duodenal‐jejunal bypass liner in obese patients with type 2 diabetes mellitus: a case control study. Diabetes Obes Metab. 2018;20(8):1868‐1877. doi:10.1111/dom.13300 - DOI - PubMed
    1. Ryder REJ, Irwin SP, Burbridge W, et al. The United Kingdom's first NHS Endobarrier service for advanced diabesity: 1‐year outcomes for all 62 treated patients. Br J Diabetes. 2019;19:110‐117. 10.15277/bjd.2019.226 - DOI
    1. Ryder REJ, Yadagiri M, Burbridge W, et al. The United Kingdom’s first NHS EndoBarrier service for long‐standing poorly controlled type 2 diabetes and obesity: outcomes one year after EndoBarrier removal. Br J Diabetes. 2021;21:76‐83. 10.15277/bjd.2021.295 - DOI